Search Results - "LIVINGSTON, R. B"

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole by Goss, P.E., Ingle, J.N., Martino, S., Robert, N.J., Muss, H.B., Livingston, R.B., Davidson, N.E., Perez, E.A., Chavarri-Guerra, Y., Cameron, D.A., Pritchard, K.I., Whelan, T., Shepherd, L.E., Tu, D.

“…MA17 showed improved outcomes in postmenopausal women given extended letrozole (LET) after completing 5 years of adjuvant tamoxifen. Exploratory subgroup…”
Get full text

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study by Wozniak, A J, Crowley, J J, Balcerzak, S P, Weiss, G R, Spiridonidis, C H, Baker, L H, Albain, K S, Kelly, K, Taylor, S A, Gandara, D R, Livingston, R B

“…Cisplatin has played a major role in the treatment of non-small-cell lung cancer (NSCLC). This randomized trial was performed by the Southwest Oncology Group…”
Get more information

Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing by GABRILOVE, Janice L, CLEELAND, Charles S, LIVINGSTON, Robert B, SAROKHAN, Brenda, WINER, Eric, EINHORN, Lawrence H

“…To prospectively evaluate the effectiveness, safety, and clinical benefits of once-weekly epoetin alfa therapy as an adjunct to chemotherapy in anemic cancer…”
Get full text

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial by KELLY, Karen, CROWLEY, John, ISRAEL, Valerie K, LIVINGSTON, Robert B, GANDARA, David R, BUNN, Paul A, PRESANT, Cary A, GREVSTAD, Patra K, MOINPOUR, Carol M, RAMSEY, Scott D, WOZNIAK, Antoinette J, WEISS, Geoffrey R, MOORE, Dennis F

“…This randomized trial was designed to determine whether paclitaxel plus carboplatin (PC) offered a survival advantage over vinorelbine plus cisplatin (VC) for…”
Get full text

Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide by Turrisi, Andrew T, Kim, Kyungmann, Blum, Ronald, Sause, William T, Livingston, Robert B, Komaki, Ritsuko, Wagner, Henry, Aisner, Seena, Johnson, David H

“…Of the approximately 170,000 cases of lung cancer diagnosed each year in the United States, 20 percent are small-cell cancers. 1 Staging systems divide…”
Get full text

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 by Ingle, J. N., Tu, D., Pater, J. L., Muss, H. B., Martino, S., Robert, N. J., Piccart, M. J., Castiglione, M., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Cameron, D. A., Palmer, M. J., Goss, P. E.

“…Background: MA.17 evaluated letrozole or placebo after 5 years of tamoxifen and showed significant improvement in disease-free survival (DFS) for letrozole…”
Get full text

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study by West, H. L., Crowley, J. J., Vance, R. B., Franklin, W. A., Livingston, R. B., Dakhil, S. R., Giguere, J. K., Rivkin, S. E., Kraut, M., Chansky, K., Gandara, D. R.

“…Background:: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer…”
Get full text

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience by Albain, K S, Crowley, J J, LeBlanc, M, Livingston, R B

“…We analyzed the 2,531-patient Southwest Oncology Group extensive-stage non-small-cell lung cancer (ENSCLC) data base from 1974 to 1988 to (1) assess the…”
Get more information

Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer by Livingston, R B, Ellis, G K, Gralow, J R, Williams, M A, White, R, McGuirt, C, Adamkiewicz, B B, Long, C A

“…We evaluated weekly single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer. After the first five patients, all received…”
Get more information

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer by Nahleh, Z. A., Barlow, W. E., Hayes, D. F., Schott, A. F., Gralow, J. R., Sikov, W. M., Perez, E. A., Chennuru, S., Mirshahidi, H. R., Corso, S. W., Lew, D. L., Pusztai, L., Livingston, R. B., Hortobagyi, G. N.

“…SWOG S0800, a randomized open-label Phase II clinical trial, compared the combination of weekly nab-paclitaxel and bevacizumab followed by dose-dense…”
Get full text

Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non–Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy by SCHILLER, Joan H, ADAK, Sudeshna, KOHMAN, Leslie, JOHNSON, David H, FEINS, Richard H, KELLER, Steven M, FRY, Willard A, LIVINGSTON, Robert B, HAMMOND, M. Elizabeth M, WOLF, Barbara, SABATINI, Linda, JETT, James

“…To determine the prognostic and predictive significance of p53 and K-ras mutations in patients with completely resected non-small-cell lung cancer (NSCLC)…”
Get full text

Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]‐sestamibi scintimammography by Mankoff, David A., Dunnwald, Lisa K., Gralow, Julie R., Ellis, Georgiana K., Drucker, Mariann J., Livingston, Robert B.

“…BACKGROUND Mammographic and physical examination assessments of the response of locally advanced breast carcinoma (LABC) to neoadjuvant therapy have been shown…”
Get full text

Samarium-153-EDTMP in Bone Metastases of Hormone Refractory Prostate Carcinoma: A Phase I/II Trial by Collins, Carolyn, Eary, Janet F, Donaldson, Gary, Vernon, Cheryl, Bush, Nigel E, Petersdorf, Stephen, Livingston, Robert B, Gordon, Edwin E, Chapman, C. Richard, Appelbaum, Frederick R

“…Samarium-153-ethylenediaminetetramethylene phosphoric acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose…”
Get full text

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer by Keller, S.M, Vangel, M.G, Adak, S, Wagner, H, Schiller, J.H, Herskovic, A, Komaki, R, Perry, M.C, Marks, R.S, Livingston, R.B, Johnson, D.H

“…This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small…”
Get full text

Randomized Study of CODE Versus Alternating CAV/EP for Extensive-Stage Small-Cell Lung Cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group by MURRAY, N, LIVINGSTON, R. B, TURRISI, A, WALDE, D, CROFT, H, OSOBA, D, OTTAWAY, J, GANDARA, D, SHEPHERD, F. A, JAMES, K, ZEE, B, LANGLEBEN, A, KRAUT, M, BEARDEN, J, GOODWIN, J. W, GRAFTON, C

“…To determine whether an intensive weekly chemotherapy regimen plus thoracic irradiation is superior to standard chemotherapy in the treatment of…”
Get full text

Infusional Paclitaxel and Weekly Vinorelbine Chemotherapy With Concurrent Filgrastim for Metastatic Breast Cancer: High Complete Response Rate in a Phase I-II Study of Doxorubicin-Treated Patients by ELLIS, G. K, GRALOW, J. R, PIERCE, H. I, WILLIAMS, M. A, LIVINGSTON, R. B

“…We investigated 96-hour paclitaxel infusion combined with weekly (days eight and 15) vinorelbine as salvage therapy for metastatic breast cancer in…”
Get full text

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base by Albain, K S, Crowley, J J, LeBlanc, M, Livingston, R B

“…We analyzed the 2,580-patient Southwest Oncology Group (SWOG) small-cell lung cancer data base from 1976 to 1988 in order to (1) determine the prognostic value…”
Get more information

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group by Gandara, D R, Crowley, J, Livingston, R B, Perez, E A, Taylor, C W, Weiss, G, Neefe, J R, Hutchins, L F, Roach, R W, Grunberg, S M

“…To test the concept that cisplatin dose-intensity is important in the treatment of non-small-cell lung cancer (NSCLC), the Southwest Oncology Group (SWOG)…”
Get more information

Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer by Lau, D H, Crowley, J J, Gandara, D R, Hazuka, M B, Albain, K S, Leigh, B, Fletcher, W S, Lanier, K S, Keiser, W L, Livingston, R B

“…A phase II study was conducted by the Southwest Oncology Group (SWOG) to assess the efficacy and toxicity of concurrent carboplatin, etoposide, and thoracic…”
Get more information

Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience by Albain, K S, Crowley, J J, Livingston, R B

“…The Southwest Oncology Group formed a database of 2,501 patients consecutively enrolled in small cell lung cancer (SCLC) trials since 1976. This report…”
Get more information